TACSTD2 and adenocarcinoma: In adenocarcinoma, high TROP2 expression was associated with the male gender (P = 0.0018), larger tumor size (>30 mm) (P = 0.016), higher pathological-stage (p-stage) (II–IV) (P = 0.012), and less tumor differentiation (moderate to poor) (P = 0.045).